Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ALADDIN: Donanemab in Adults With Down Syndrome
NCT06911944Phase 4Not yet recruiting
- Sponsor
- Michael Rafii
- Start
- Aug 2026
- Primary completion
- Dec 2028
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
01
Overview
Phase 4, randomised, double-blind trial in Alzheimer's disease (AD) comparing Donanemab with Placebo (2 arms). Primary endpoint: Change from baseline on brain amyloid levels at 12 months. Planned start Aug 2026; status: not yet recruiting.
02
Drugs
donanemab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT06911944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06911944.